<DOC>
	<DOCNO>NCT00350948</DOCNO>
	<brief_summary>The purpose research study determine TelcytaÂ® give combination liposomal doxorubicin effective liposomal doxorubicin alone treat woman recurrent ovarian epithelial cancer , fallopian tube cancer primary peritoneal cancer refractory resistant platinum chemotherapy .</brief_summary>
	<brief_title>Phase 3 Randomized Study Telcyta + Doxorubicin Versus Doxorubicin Platinum Refractory Resistant Ovarian Cancer</brief_title>
	<detailed_description>This randomize , open label , multicenter , multinational Phase 3 study TLK286 ( Telcyta ) combination liposomal doxorubicin ( Doxil/Caelyx ) compare active control therapy liposomal doxorubicin ( Doxil/Caelyx ) second line therapy patient platinum refractory resistant recurrent ovarian cancer . Patients randomly assign receive either TLK286 ( Telcyta ) combination liposomal doxorubicin ( Doxil/Caelyx ) active control liposomal doxorubicin ( Doxil/Caelyx ) .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>Are woman 18 year age old Have histologically cytologically confirm epithelial cancer primary peritoneal cancer Have platinum refractory resistant cancer Measurable disease accord radiographic RECIST criterion progression Had treatment firstline chemotherapy platinumcontaining regimen Have clinically significant cardiac disease Have sign intestinal obstruction interfere nutrition Are pregnant lactating Had prior treatment liposomal doxorubicin Had prior treatment Telcyta</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Ovary</keyword>
</DOC>